CASI Pharmaceuticals, Inc.
CASIFDrugs in Pipeline
11
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
Get an email about CASIF's next catalysts
Track CASI Pharmaceuticals (CASIF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Sunitinib Malate
Metastatic Renal Cell Carcinoma
recombinant human Angiostatin protein
Carcinoma, Non-Small-Cell Lung
Panzem NCD
Recurrent Glioblastoma Multiforme
Panzem Nanocrystal Colloidal Dispersion
Recurrent Glioblastoma Multiforme
ENMD-2076
Advanced Adult Hepatocellular Carcinoma
MKC-1
Pancreatic Cancer
Panzem Nanocrystal Colloidal Dispersion (NCD)
Ovarian Cancer
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Carcinoid Tumor
2-methoxyestradiol
Relapsed Multiple Myeloma
Panzem® NCD
Prostate Cancer
CID-103
Antibody Mediated Rejection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sunitinib Malate | Phase 2 | Metastatic Renal Cell Carcinoma | - | |
recombinant human Angiostatin protein | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Panzem NCD | Phase 2 | Recurrent Glioblastoma Multiforme | - | - |
Panzem Nanocrystal Colloidal Dispersion | Phase 2 | Recurrent Glioblastoma Multiforme | - | - |
ENMD-2076 | Phase 2 | Advanced Adult Hepatocellular Carcinoma | - | - |
MKC-1 | Phase 2 | Pancreatic Cancer | - | - |
Panzem Nanocrystal Colloidal Dispersion (NCD) | Phase 2 | Ovarian Cancer | - | - |
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) | Phase 2 | Carcinoid Tumor | - | - |
2-methoxyestradiol | Phase 2 | Relapsed Multiple Myeloma | - | - |
Panzem® NCD | Phase 2 | Prostate Cancer | - | - |
CID-103 | Phase 2 | Antibody Mediated Rejection | - | - |
Recurrent Glioblastoma Multiforme
2 drugs in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Metastatic Renal Cell Carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in CASI Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in CASI Pharmaceuticals, Inc.'s (CASIF) pipeline across Phase 2. Its lead program is 2-methoxyestradiol (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CASI Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CASI Pharmaceuticals, Inc. (CASIF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CASIF biotech catalysts?→
Add CASIF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CASI Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.